(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(-0.08%) $82.74
(0.24%) $1.657
(-0.41%) $2 328.70
(-0.44%) $27.23
(-0.23%) $913.70
(-0.03%) $0.934
(0.02%) $10.99
(-0.01%) $0.802
(0.01%) $92.33
Live Chart Being Loaded With Signals
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases...
Stats | |
---|---|
Today's Volume | 240 936 |
Average Volume | 136 245 |
Market Cap | 129.76M |
EPS | €0 ( 2024-04-21 ) |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -4.78 |
ATR14 | €0.0160 (0.28%) |
Volume Correlation
Ose Immunotherapeutics SA Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ose Immunotherapeutics SA Correlation - Currency/Commodity
Ose Immunotherapeutics SA Financials
Annual | 2023 |
Revenue: | €2.23M |
Gross Profit: | €2.23M (100.00 %) |
EPS: | €-1.180 |
Q4 | 2023 |
Revenue: | €869 000 |
Gross Profit: | €869 000 (100.00 %) |
EPS: | €-0.540 |
Q2 | 2023 |
Revenue: | €1.36M |
Gross Profit: | €1.36M (100.00 %) |
EPS: | €-0.640 |
Q4 | 2022 |
Revenue: | €2.26M |
Gross Profit: | €2.26M (100.00 %) |
EPS: | €-0.860 |
Financial Reports:
No articles found.
Ose Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators